Home › Compare › IPCIF vs RYLD

IPCIF vs RYLD: Dividend Comparison 2026

IPCIF yields 1333.33% · RYLD yields 12.39%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPCIF wins by $241528700.56M in total portfolio value
10 years
IPCIF
IPCIF
● Live price
1333.33%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$241528700.61M
Annual income
$210,475,860,072,406.56
Full IPCIF calculator →
RYLD
RYLD
● Live price
12.39%
Share price
$14.64
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.3K
Annual income
$2,682.98
Full RYLD calculator →

Portfolio growth — IPCIF vs RYLD

📍 IPCIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPCIFRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPCIF + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IPCIF pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPCIF
Annual income on $10K today (after 15% tax)
$113,333.33/yr
After 10yr DRIP, annual income (after tax)
$178,904,481,061,545.56/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,053.44/yr
After 10yr DRIP, annual income (after tax)
$2,280.53/yr
At 15% tax rate, IPCIF beats the other by $178,904,481,059,265.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPCIF + RYLD for your $10,000?

IPCIF: 50%RYLD: 50%
100% RYLD50/50100% IPCIF
Portfolio after 10yr
$120764350.33M
Annual income
$105,237,930,037,544.77/yr
Blended yield
87.14%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPCIF buys
0
RYLD buys
0
No recent congressional trades found for IPCIF or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPCIFRYLD
Forward yield1333.33% ✓12.39%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$241528700.61M ✓$45.3K
Annual income after 10y$210,475,860,072,406.56 ✓$2,682.98
Total dividends collected$239239876.27M ✓$19.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: IPCIF vs RYLD ($10,000, DRIP)

YearIPCIF PortfolioIPCIF Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$144,033$133,333.33$11,939$1,239.34+$132.1K → IPCIF
2$1,948,924$1,794,807.89$14,158$1,382.89+$1.93M → IPCIF
3$24,782,219$22,696,870.86$16,682$1,532.59+$24.77M → IPCIF
4$296,245,945$269,728,970.81$19,537$1,687.64+$296.23M → IPCIF
5$3,330,378,004$3,013,394,842.54$22,752$1,847.20+$3330.36M → IPCIF
6$35,223,684,321$31,660,179,856.69$26,355$2,010.43+$35223.66M → IPCIF
7$350,636,384,108$312,947,041,885.16$30,376$2,176.45+$350636.35M → IPCIF
8$3,286,630,500,315$2,911,449,569,318.85$34,847$2,344.43+$3286630.47M → IPCIF
9$29,021,346,295,663$25,504,651,660,325.88$39,800$2,513.54+$29021346.26M → IPCIF
10$241,528,700,608,766$210,475,860,072,406.56$45,269$2,682.98+$241528700.56M → IPCIF

IPCIF vs RYLD: Complete Analysis 2026

IPCIF — Stock

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Full IPCIF Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this IPCIF vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPCIF vs SCHDIPCIF vs JEPIIPCIF vs OIPCIF vs KOIPCIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.